Research programme: MASTL inhibitors - Pfizer
Latest Information Update: 08 Jul 2024
At a glance
- Originator Pfizer
- Class Antineoplastics; Naphthyridines; Small molecules
- Mechanism of Action MASTL protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Preclinical trials in Cancer in USA (PO) before April 2024
- 05 Apr 2024 Pharmacodynamics data from the preclinical studies in Cancer presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 04 Jan 2024 Pfizer files a world patent for '2,7-naphthyridine compounds as mastl inhibitors'